Cargando…

Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation

Event-free survival (EFS) is considered the most reliable surrogate endpoint for overall survival (OS) in randomised controlled trials (RCTs) of adjuvant therapies for malignant tumours. However, the surrogacy of intermediate endpoints such as EFS for OS in trials of patients with osteosarcoma has n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Kazuhiro, Kawano, Masanori, Iwasaki, Tatsuya, Matsuda, Shogo, Itonaga, Ichiro, Tsumura, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244479/ https://www.ncbi.nlm.nih.gov/pubmed/32444660 http://dx.doi.org/10.1038/s41598-020-65591-z

Ejemplares similares

Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation
por: Tanaka, Kazuhiro, et al.
Publicado: (2019)

A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

Interaction between human osteosarcoma and mesenchymal stem cells via an interleukin-8 signaling loop in the tumor microenvironment
por: Kawano, Masanori, et al.
Publicado: (2018)

Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report
por: Matsuda, Shogo, et al.
Publicado: (2020)

Analysis of the signal cross talk via CCL26 in the tumor microenvironment in osteosarcoma
por: Kawano, Masanori, et al.
Publicado: (2021)

Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma
por: Kubota, Yuta, et al.
Publicado: (2022)

microRNA-93 promotes cell proliferation via targeting of PTEN in Osteosarcoma cells
por: Kawano, Masanori, et al.
Publicado: (2015)

The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells
por: KAWANO, MASANORI, et al.
Publicado: (2023)

Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma
por: Kawano, Masanori, et al.
Publicado: (2012)

c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing’s Sarcoma Cell Line
por: Kawano, Masanori, et al.
Publicado: (2015)

MicroRNA-181c prevents apoptosis by targeting of FAS receptor in Ewing’s sarcoma cells
por: Kawano, Masanori, et al.
Publicado: (2018)

A meta-analysis of randomized controlled trials that compare standard doxorubicin with other first-line chemotherapies for advanced/metastatic soft tissue sarcomas
por: Tanaka, Kazuhiro, et al.
Publicado: (2019)

Osteomyelitis of the Distal Phalanx of the Thumb due to Parvimonas micra and Fusobacterium nucleatum: A Case Report
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

Tumor-suppressive microRNA-152 inhibits the proliferation of Ewing’s sarcoma cells by targeting CDK5R1
por: Kawano, Masanori, et al.
Publicado: (2023)

Patellar dislocation following distal femoral replacement after extra-articular knee resection for bone sarcoma: A case report
por: Kubota, Yuta, et al.
Publicado: (2022)

Primary clear cell sarcoma of the femur: a unique case with RT-PCR and direct sequencing confirmation of EWSR1/ATF1 fusion gene
por: Kubota, Yuta, et al.
Publicado: (2021)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma
por: Liu, Hua, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists
por: Methy, Nicolas, et al.
Publicado: (2010)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gg1d0aeh33g8spl5vh0ipqo3u4